Hamartoma pathophysiology

Revision as of 22:04, 8 December 2015 by Maria Villarreal (talk | contribs)
Jump to navigation Jump to search

Hamartoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hamartoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hamartoma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hamartoma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hamartoma pathophysiology

CDC on Hamartoma pathophysiology

Hamartoma pathophysiology in the news

Blogs on Hamartoma pathophysiology

Directions to Hospitals Treating Hamartoma

Risk calculators and risk factors for Hamartoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

Hamartomas arise from connective tissue and are generally formed of cartilage, fat, and connective tissue cells, although they may include many other types of cells. They can be located in lung (most common), heart, hypothalamus, kidneys, or spleen. There are many genetic syndromes that cause multiple hamartomas, such as; Peutz-Jeghers syndrome, PTEN hamartoma tumour syndrome and Cowden’s syndrome . Genes involved in the pathogenesis of harmatomatous syndromes include;BMPR1A, SMAD4, PTEN and STK11.[1]

Pathogenesis

Hamartomas result from an abnormal formation of normal tissue, although the underlying reasons for the abnormality are not fully understood. They grow along with, and at the same rate as, the organ from whose tissue they are made, and, unlike cancerous tumors, only rarely invade or compress surrounding structures significantly. [2]

Lung

The most common hamartomas occur in the lungs. About 5-8% of all solitary lung tumors, about 75% of all benign lung tumors are hamartomas. They almost always arise from connective tissue and are generally formed of cartilage, fat, and connective tissue cells, although they may include many other types of cells. The great majority of them form in the connective tissue on the outside of the lungs, although about 10% form deep in the linings of the bronchii. They can be worrisome, especially if situated deep in the lung, as it is important and sometimes difficult to distinguish them from malignancies. An x-ray will often not provide definitive diagnosis, and even a CT scan may be insufficient if the hamartoma atypically lacks cartilage and fat cells. Lung hamartomas are more common in men than in women and may present additional difficulties in smokers.

Some lung hamartomas can compress surrounding lung tissue to a degree, but this is generally not debilitative or even noticed by the patient, especially for the more common peripheral growths. They are treated, if at all, by surgical resection, with an excellent prognosis: generally, the only real danger is the inherent possibility of surgical complications.

Heart

Cardiac rhabdomyomas are hamartomas comprised of altered cardiac myocytes that contain large vacuoles and glycogen. They are the second most common tumor of the heart in children and infants (after fibromas). There is a strong association between cardiac rhabdomyomas and tuberous sclerosis (characterized by hamartomas of the central nervous system, kidneys and skin, as well as pancreatic cysts; 25-50% of patients with cardiac rhabdomyomas will have tuberous sclerosis, and up to 100% of patients with tuberous sclerosis will have cardiac masses by echocardiography. Symptoms depend on the size of the tumor, its location relative to the conduction system, and whether it obstructs blood flow. Symptoms are usually from congestive heart failure (in utero heart failure may occur). If patients survive infancy, their tumors may regress spontaneously; resection in symptomatic patients has good results.

Hypothalamus

One of the most troublesome hamartomas occurs on the hypothalamus. Unlike most such growths, a hypothalamic hamartoma is symptomatic; it most often causes gelastic seizures, and can cause visual problems, other seizures, rage disorders associated with hypothalamic diseases, and early onset of puberty. The symptoms typically begin in early infancy and are progressive, often into general cognitive and/or functional disability. Moreover, resection is usually difficult, as the growths are generally adjacent to, or even intertwined with, the optic nerve; however, the symptoms are resistant to medical control. Surgical techniques are improving and can result in immense improvement of prognosis.

Kidneys, spleen, and other vascular organs

One general danger of hamartoma is that they may impinge into blood vessels, resulting in a risk of serious bleeding. Because hamartoma typically lacks elastic tissue, it may lead to the formation of aneurysms and thus possible hemorrhage. Where a hamartoma impinges into a major blood vessel, such as the renal artery, hemorrhage must be considered life-threatening.

Hamartoma of the kidney is also called angiomyolipoma and can be associated with tuberous sclerosis. It is one of the more frequently seen hamartomas. The condition is more prevalent in women than men, and generally occurs in the right kidney. Hamartomas of the spleen are uncommon, but can be dangerous. About 50% of such cases manifest abdominal pain] and they are often associated with hematologic abnormalities and spontaneous rupture.

Genetics

Genes involved in the pathogenesis of harmatomatous syndromes include BMPR1A, SMAD4, PTEN and STK11.[3]

Associated Conditions

Many hereditary syndromes are associated with hamartomatous formation. The familial inheritance diseases include; juvenile polyposis syndrome, Peutz-Jeghers syndrome, hereditary mixed polyposis syndrome (HMPS) and PTEN hamartoma tumour syndrome, tuberous sclerosis, Cowden’s syndrome and Bannayan-Riley-Ruvalcaba syndrome.

Cowden syndrome

Cowden syndrome is a serious genetic disorder [4]characterized by multiple hamartomas. Usually skin hamartomas exist, and commonly (about 66% of cases) hamartoma of the thyroid gland exists. Additional growths can form in many parts of the body, especially in mucosa, the GI tract, bones, CNS, the eyes, and the genitourinary tract. The hamartomas themselves may cause symptoms or even death, but morbidity is more often associated with increased occurrence of malignancies, usually in the breast or thyroid.

Tuberous sclerosis

Tuberous sclerosis is a syndrome caused by potentially by more than 900 mutations of the tumor suppressor genes for tuberin (TSC2) and hamartin (TSC1) that cause abnormal cellular signaling through rapamycin complex 1It is characterized by multiple hamartomas, angiomyolipomas (in 80%) and lymphangioleiomyomatosis usually in women. Important clinical features include; Epilepsy,learning difficulties, and skin tumors.

Gross Pathology

On gross pathology, a hallmark feature of hamartoma is a well-circumscribed mass that may show a variegated yellow and white appearance, which corresponds respectively to fat and cartilage.[5]

Microscopic Pathology

On microscopic pathology, hamartomas have benign tumors features, such as; disorganized (non-neoplastic) growth, tissue of the region within it is found and no invasion to surrounding tissue or structures.[5]

Common findings include:

Cartilage

  • Single cells in lacunae surrounded by abundant matrix
  • Paucicellular vis-a-vis malignant lesions

Fat (adipocytes)

  • Respiratory epithelium (columnar epithelium with cilia) - lung hamartoma


Gallery

References

  1. Stojcev Z, Borun P, Hermann J, et al. Hamartomatous polyposis syndromes. Hered Cancer Clin Pract. 2013;11(1):4.
  2. Zakharov V, Schinstine M (2008). "Hamartoma of the lung". Diagn. Cytopathol. 36 (5): 331–2. doi:10.1002/dc.20790. PMID 18418855.
  3. Stojcev Z, Borun P, Hermann J, et al. Hamartomatous polyposis syndromes. Hered Cancer Clin Pract. 2013;11(1):4.
  4. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z; et al. (1997). "Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome". Nat Genet. 16 (1): 64–7. doi:10.1038/ng0597-64. PMID 9140396.
  5. 5.0 5.1 Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology. Elsevier Health Sciences; 2012.
  6. 6.0 6.1 6.2 6.3 Hamartoma. Libre Pathology.http://librepathology.org/wiki/index.php/Pulmonary_hamartoma Accessed on December 8, 2015


Template:WikiDoc Sources